Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received two drug license suspension orders from Drugs Control Administration authorities in Karnataka. The first suspension is for a store in Madikeri, Kohinoor Road, suspended for 2 days with order received on 22.05.2026, citing violations under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945. The second suspension is for a store in Nagarabhavi 2nd Stage, Bangalore, suspended for 3 days under the same regulatory framework. The combined potential revenue loss from both suspensions is estimated at Rs 2.52 lakhs (Rs 0.54 lakhs + Rs 1.98 lakhs). The company has disclosed this update as required under SEBI Listing Regulations.
The financial impact is minimal at approximately Rs 2.52 lakhs, representing a very small portion of the company's operations. However, it highlights compliance risks at the subsidiary level that investors should monitor, particularly for a retail pharmacy chain where drug license compliance is critical to operations.